newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint Positive data from this proof-of-concept study demonstrate that short-term sy